FBIO vs. CMRX, ACHV, SGMO, AGEN, RGLS, VSTM, CRIS, BOLT, SABS, and MTEM
Should you be buying Fortress Biotech stock or one of its competitors? The main competitors of Fortress Biotech include Chimerix (CMRX), Achieve Life Sciences (ACHV), Sangamo Therapeutics (SGMO), Agenus (AGEN), Regulus Therapeutics (RGLS), Verastem (VSTM), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), and Molecular Templates (MTEM). These companies are all part of the "medical" sector.
Chimerix (NASDAQ:CMRX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Chimerix currently has a consensus target price of $8.50, suggesting a potential upside of 855.06%. Fortress Biotech has a consensus target price of $28.50, suggesting a potential upside of 1,166.67%. Given Chimerix's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Chimerix.
Fortress Biotech has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.
45.4% of Chimerix shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 13.1% of Chimerix shares are held by company insiders. Comparatively, 33.4% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Fortress Biotech has a net margin of -69.13% compared to Fortress Biotech's net margin of -25,337.96%. Chimerix's return on equity of 0.00% beat Fortress Biotech's return on equity.
In the previous week, Fortress Biotech had 4 more articles in the media than Chimerix. MarketBeat recorded 6 mentions for Fortress Biotech and 2 mentions for Chimerix. Fortress Biotech's average media sentiment score of 1.10 beat Chimerix's score of 0.38 indicating that Chimerix is being referred to more favorably in the media.
Chimerix has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.
Chimerix received 60 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.92% of users gave Fortress Biotech an outperform vote while only 63.59% of users gave Chimerix an outperform vote.
Summary
Fortress Biotech beats Chimerix on 13 of the 17 factors compared between the two stocks.
Get Fortress Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fortress Biotech Competitors List
Related Companies and Tools
Free FBIO Stock Alerts